Today, October 13, 2017, the subscription period of 2cureX AB's ("2cureX") new share issue will begin prior to scheduled listing on Nasdaq Stockholm First North. Subscription period expires on 27 October 2017. In the case of a fully subscribed new share issue, 2cureX is totaled approximately SEK 18.3 million before issue costs. Emission liquidity is intended to fund all preparatory activities for market launch of IndiTreat ™, which includes CE marking and ISO certification, sales organization building, revenue recognition strategies and establishment of additional validation sites in Germany, England and France. 2cureX has agreed in advance in writing about subscriptions of a total of approximately SEK 9.2 million, corresponding to approximately 50 percent of the issue fee. Memorandum, teaser and application for subscription of shares are available at 2cureX's (www.2curex.com ) and Sedermera Fondkommission ( www.sedermera.se ) and websites. In addition, there is the possibility to subscribe for shares with Bank ID on the Sedermera Fund Commission website. Sedermera Fondkommission is 2cureX's financial adviser in connection with the rights issue and the planned listing on Nasdaq Stockholm First North.

For every ten (10) owned shares in the Company on the record date (17.07.2020), one (1) warrant of series TO1 will be received. Each warrant of series TO1 will give the holder the right to subscribe for one (1) new share at a subscription price corresponding to 70 percent of the average volume-weighted share price according to Nasdaq First North Growth Market’s official price statistics during the period from April 9, 2021 to April 22, 2021.

Update (13.07.2020): Record date for allotment of warrants of series TO1 is set to July 17, 2020.

Update (04.08.2020): First day for trading in TO1 series warrants.